Long-Term Safety and Efficacy of Two Different Antimuscarinics, Imidafenacin and Solifenacin, for Treatment of Overactive Bladder: A Prospective Randomized Controlled Study

Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial

(2011) Y.-S. Lee et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Discontinuation Rates of Anticholinergic Medications Used for the Treatment of Lower Urinary Tract Symptoms

(2010) Manish Gopal et al.   OBSTETRICS AND GYNECOLOGY

Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence

(2009) Karl-Erik Andersson et al.   CURRENT OPINION IN UROLOGY

A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder

(2009) Yukio Homma et al.   INTERNATIONAL JOURNAL OF UROLOGY

The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study

(2008) Karin S. Coyne et al.   BJU INTERNATIONAL

A review of adherence to drug therapy in patients with overactive bladder

(2008) Ramandeep K. Basra et al.   BJU INTERNATIONAL

Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder

(2008) Yukio Homma et al.   INTERNATIONAL JOURNAL OF UROLOGY